TLDR Some leukemia treatments can cause skin reactions similar to keratosis pilaris.
The document reviews the occurrence of keratosis pilaris (KP)-like eruptions in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs), focusing on a case involving imatinib. It highlights that such skin reactions, though rare with imatinib, are more common with second-generation TKIs like nilotinib and dasatinib. In a study of 39 CML patients, 23% developed extensive KP, 41% had scalp alopecia, and 38.5% experienced body hair loss. Histopathological examinations showed follicular atrophy and perifollicular fibrosis. The review underscores the importance of recognizing and managing these dermatological side effects in CML patients treated with TKIs.
5 citations,
January 2021 in “Indian Journal of Pharmacology” Nilotinib can cause generalized keratosis pilaris.
19 citations,
April 2016 in “Case Reports in Dermatology” Nilotinib can cause keratosis pilaris, a skin condition.
32 citations,
September 2015 in “Dermatology” Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.
25 citations,
November 2013 in “Journal of the American Academy of Dermatology” Many patients on new leukemia drugs had mild to moderate skin reactions.
4 citations,
October 2013 in “PLoS ONE” Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.
82 citations,
March 2013 in “PLoS ONE” Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.
42 citations,
April 2012 in “Seminars in Oncology” Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
32 citations,
September 2015 in “Dermatology” Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.
88 citations,
July 2014 in “Journal of the American Academy of Dermatology” Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
January 2018 in “Springer eBooks” Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.
26 citations,
February 2015 in “Pediatric blood & cancer” Targeted anticancer therapies in children often cause skin side effects like rash and dry skin.
